Table 1 Summary of changes in modified total Sharp score from baseline of the ADEPT to week 144 of adalimumab treatment*
Change in mTSS†Placebo/adalimumab‡ N (%)Adalimumab N (%)95% CI§
Baseline to week 24, N128115
    Decrease/no change90 (70.3)103 (89.6)82.5 to 94.5
    Increase38 (29.7)12 (10.4)5.5 to 17.5
Baseline to week 48, N128115
    Decrease/no change94 (73.4)102 (88.7)81.4 to 93.8
    Increase34 (26.6)13 (11.3)6.2 to 18.6
Week 24 to week 48, N128115
    Decrease/no change105 (82.0)99 (86.1)78.4 to 91.8
    Increase23 (18.0)16 (13.9)8.2 to 21.6
Baseline to week 144, N128115
    Decrease/no change88 (68.8)91 (79.1)70.6 to 86.1
    Increase40 (31.3)24 (20.9)13.9 to 29.4
Week 24 to week 144, N128115
    Decrease/no change99 (77.3)89 (77.4)68.7 to 84.7
    Increase29 (22.7)26 (22.6)15.3 to 31.3
Week 48 to week 144, N128115
    Decrease/no change104 (81.3)92 (80.0)71.5 to 86.9
    Increase24 (18.8)23 (20.0)13.1 to 28.5

  • Decrease is <−0.5 change; no change was −0.5 to 0.5 change; increase was >0.5 change.

  • *Patients included in this analysis are those who had a radiographic measure at baseline, week 24, week 48 and at week 96 or week 144. Data are imputed; for patients who did not have a week 144 modified total Sharp score (mTSS), the week 96 mTSS was used.

  • †Data are imputed; for patients who did not have a week 144 mTSS, the week 96 mTSS was used.

  • ‡Patients who were randomly assigned to receive placebo during the double-blind phase of the study began receiving open-label adalimumab 40 mg every other week starting at week 24.

  • §An exact 95% CI was constructed based on the binomial distribution for the adalimumab group.

  • ADEPT, Adalimumab Effectiveness in Psoriatic Arthritis Trial.